Recurrent Adult Brain Neoplasm
18
0
1
13
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
16.7%
3 terminated out of 18 trials
81.3%
-5.3% vs benchmark
0%
0 trials in Phase 3/4
69%
9 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (18)
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma